MetaCap

Cadrenal Therapeutics (CVKD) vs MetaVia (MTVA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cadrenal Therapeutics is the larger company by market cap ($7.0 million vs $6.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CVKD+74.84%MTVA-30.82%
+100%+31%-37%
Oct 7, 20261 yearNov 20, 2026
CVKD+86.79%MTVA-28.37%
+93%+29%-34%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CVKD versus MTVA key metrics
MetricCVKDMTVA
Share price$1.70$1.01
Market cap$7.01M$6.81M
1-day change+0.59%-7.34%
EPS (TTM)$-3.67$-2.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-13.24M$-12.97M
52-week high$12.50$13.42
52-week low$0.816$0.966
Distance from 52-week high-86.40%-92.47%
Analyst consensusnonenone
Avg. price target upside+723.53%+1813.86%
Average volume496.14K113.44K
Shares outstanding4.12M6.74M
Employees58
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Cadrenal Therapeutics

CVKD stock →

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About MetaVia

MTVA stock →

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

CVKD vs MTVA FAQ

Which is bigger, Cadrenal Therapeutics or MetaVia?

Cadrenal Therapeutics (CVKD) is larger, with a market capitalization of $7.01M compared with $6.81M for MetaVia (MTVA).

Are Cadrenal Therapeutics and MetaVia in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons